CRISPR Therapeutics AG vs Johnson & Johnson — Stock Comparison
CRISPR Therapeutics AG (CRSP) and Johnson & Johnson (JNJ) are both listed on US exchanges. This page compares their Q·Score ratings, key fundamentals (P/E, margins, growth), and Wall Street analyst consensus side by side. Data sourced from Yahoo Finance and updated on each page load.
Johnson & Johnson scores ahead of CRISPR Therapeutics AG on Q·Score (7.1 vs 5.9 out of 10), led by Quality (9.3 vs 1.6) and Valuation (7.3 vs 6.9). CRISPR Therapeutics AG scores higher on Health, reflecting stronger balance sheet strength. Analyst consensus targets imply greater upside for CRSP (+54.4%) than for JNJ (+10.7%).
Price Performance
Normalised to 100 at period start — shows relative performance.
Q·Score Breakdown
Clean balance sheet with low leverage (0.4× debt-to-equity).
⚠ low return on equity (-31%).
High-quality business with 26% return on equity and 22% profit margins.
⚠ earnings contracting 53% year-over-year.
Analyst Consensus
Fundamentals
Frequently Asked Questions
CRSP vs JNJ: which stock scores better overall?
Based on Q·Score, Johnson & Johnson (JNJ) scores 7.1/10 versus CRISPR Therapeutics AG (CRSP) at 5.9/10. The Q·Score measures five dimensions: Quality, Health, Growth, Valuation, and Sentiment. For informational purposes only — not financial advice.
Which has better revenue growth: CRSP or JNJ?
CRISPR Therapeutics AG (CRSP) scores higher on Growth (6.8/10 vs 5.1/10). CRISPR Therapeutics AG reports revenue growth (68.6% YoY) while Johnson & Johnson reports (9.9% YoY). Growth scores reflect revenue and earnings momentum relative to sector peers.
Is CRSP or JNJ more attractively valued?
Johnson & Johnson (JNJ) scores higher on Valuation (7.3/10 vs 6.9/10). Valuation is assessed using P/E ratio, analyst price targets, and 52-week range positioning relative to sector peers.
What do analysts say about CRSP vs JNJ?
There are 21 analysts covering CRSP with a consensus price target of $83.52, and 23 analysts covering JNJ with a consensus target of $252.87. Analyst consensus ratings are aggregated from Wall Street research and do not constitute investment advice.
Which is more profitable: CRSP or JNJ?
Johnson & Johnson (JNJ) scores higher on Quality (9.3/10 vs 1.6/10). Net profit margin: CRSP at 0.0%, JNJ at 21.8%. Quality scores reflect profit margins, return on equity, and free cash flow generation.
Which has stronger financial health: CRSP or JNJ?
CRISPR Therapeutics AG (CRSP) scores higher on Financial Health (8.7/10 vs 6.5/10). Market beta: CRSP at 1.70, JNJ at 0.26. Health scores consider beta, debt-to-equity, and current ratio. All investments carry risk — this is not investment advice.
What are the market caps of CRSP and JNJ?
CRISPR Therapeutics AG (CRSP) has a market capitalisation of $5.3B, while Johnson & Johnson (JNJ) has a market cap of $549.8B. Market cap data is sourced from Yahoo Finance and reflects the most recent available figures.
Related Comparisons
Q·Score is an educational tool and is not financial advice. Data provided by Yahoo Finance. Updated on each page load. How it's calculated →